Summary Since prostacyclin (PGI2) is known to have a cytoprotective effect on epithelia, and since cigarette smoking is associated with an increased risk of bladder cancer, we investigated the possibility that nicotine, cotinine (the prinicpal metabolite of nicotine) and other components of cigarette smoke inhibit PGI2 secretion by the urinary bladder.
The mammalian bladder synthesises the prostanoid prostacyclin (PGI2) in quantities comparable to vascular tissue (Jeremy et al., 1984a,b) . Although a role for PGI2 in this organ has yet to be defined (Jeremy et al., 1984a) , it is possible that this prostanoid (and certain other PGs) may play a cytoprotective role in the bladder, similar to that documented for the gastrointestinal system (Konturek et al., 1981a,b; Yik et al., 1982) , where certain prostanoids have even been used successfully to treat peptic ulceration (Vantrappen et al., 1983) . Evidence supporting the view that PGs play a cytoprotective role in the urinary bladder is provided by the finding that local administration of PGE2 improves symptoms caused by schistosomal ulcers (El. Gendi et al., 1982) and has also been used successfully to treat cyclophosphamideinduced haemorrhagic cystitis (Mohiuddin et al., 1984) . Diminution of local PGI2 synthesis may therefore reduce the cytoprotective capacity of the urothelium, rendering it more susceptible to the actions of carcinogens which may be present in the urine.
Cigarette smoking is linked epidemiologically with an increased incidence of bladder cancer, although the mechanisms involved remain undefined (Morrison et al., 1984) . A major component of cigarette smoke, nicotine, has been shown to inhibit PGI2 synthesis in vascular tissue models (Alster et al., 1983) . We have also shown that cigarette smoke extracts, in vitro, inhibit vascular PGI2 synthesis (unpublished observations). We therefore studied the effect of nicotine, cotinine ((Matsukura et al., 1984) ) and cigarette smoke extracts on in vitro PGI2 synthesis by the rat urinary bladder. We also studied the effect of 2-naphthylamine on PGI2 synthesis, since this substance is a known bladder carcinogen (Schmeltz & Hoffman, 1977 (Schmeltz & Hoffman, 1977; Government Chemist, 1974) (37°C) . At the end of incubation, the sample was centrifuged and an aliquot of the supernatant was collected and diluted with radioimmunoassay buffer for estimation of 6-oxo-PGF1a (the stable, spontaneous metabolite of PGI2) concentration, using a specific radioimmunoassay (see details below). Nicotine free base and nicotine sulphate produced identical effects and therefore the results have been summated.
Radioimmunoassay of 6-oxo-PGF,a Antisera for 6-oxo-PGF1a assays were purchased from Cappel Laboratories, West Chester, Pa., USA, and [3H]-6-oxo-PGFpa (160 Ci mmol 1) from New England Nuclear, Boston, Ma., USA, Unlabelled 6-oxoPGFpa was a gift from Upjohn Co., Kalamzoo, Mi., USA. Assays were carried out according to protocols obtained from Cappel Laboratories (Jeremy et al., 1984a,c; .
(ii) Effect of carcinogens on spontaneous release of PGI2 by bladder tissue The known bladder carcinogen, 2-napthylamine (Schmeltz & Hoffman, 1977) , was studied as in (i) above, Quinoline, Nalkyl carbazole, hydrazine, and dibenzocarbazole as tumour initiators or accelerators (Schmeltz & Hoffman, 1977) , were also studied. These chemicals were purchased from BDH, Poole, Dorset, UK.
(iii) Effect of ECSE, nicotine, cotinine and 2-naphtylamine on 14C-arachidonic acid conversion into 6-oxo-PGF1c by rat urinary bladder tissue Conversion of 14C-arachidonic acid (14C-AA) into 6-oxo-PGFca was carried out as previously described (Jeremy et al., , 1985 (Jeremy et al., , 1985 . The zones corresponding to 6-oxo-PGF1a and AA were cut and assayed for radioactivity by liquid scintillation counting and % conversion of 14C-AA to 14C-6-oxo-PGFpx was calculated (Nadler et al., 1983; Chechoway et al., 1983) .
Statistical analysis and presentation of data Data are presented as median and range (Altman et al., 1983) . Results in control experiments are compared with those in the presence of agents or extracts being evaluated using a non-parametric Mann-Whitney test (two-tailed) (Altman et al., 1983) Results (i) Effect of cigarette smoke (bubbled through KrebsRinger bicarbonate buffer; CS-KRB) on spontaneous in vitro release of PGI2 (measured as 6-oxo-PGF1L): Table I CS-KRB was significantly (P <0.01) inhibitory to in vitro PGI2 at 0.05 cigarette equivalents ml. Higher CS-KRB concentrations produced progressively more severe inhibition of PGI2 release. The inhibitory trend of CS-KRB was evident at 0.0125 and 0.025 cigarette equivalents ml-', but this did not achieve statistical significance.
(ii) Effect of ethanolic cigarette smoke extracts (ECSE) on spontaneous in vitro PGI2 release (measured as 6-oxo-PGF1c): Table II Results were very similar to those described in (i) above. The inhibitory trend was again evident at concentrations below those which showed statistical significance.
(iii) The effect of nicotine and cotinine on spontaneous in vitro release of PGI2 (measured as 6-oxo-PGF1ax): All statistical comparisons were not significant. Table III Up to lgl-' concentrations of both nicotine and its main metabolite, cotinine, did not inhibit PGI2 release.
(iv) Effect of ethanolic cigarette smoke extracts (ECSE) on the conversion of 14C arachidonic acid (14C-AA) to 6-oxo-PGF1a: Table IV ECSE significantly inhibited the conversion of 14C-AA to 6-oxoPGF1a at concentrations of 0.25 gI-1 and above.
(v) Effect of nicotine and cotinine on the conversion of 14C-arachidonic acid (14C-AA) to 6-oxo-PGF1a: release (assessed as 6-oxo-PGF,a) from rat bladder tissue. 6-oxo-PGF,a (ng 20mg tissue-' 60min-1) is expressed as median and 
Discussion
We have previously demonstrated that the rat and cat urinary bladder produce PGI2 (Jeremy et al., 1984a,b) . The relative contributions of the bladder urothelium and muscle layers to local PGI2 production are undefined at present. However, it is clear that substantial amounts of PGI2 are released into the lumen of isolated whole rat bladders, in vitro (Jeremy et al., 1984a) . The exact role, if any, played by this prostanoid and by the smaller amounts of other prostanoids also synthesised by the bladder, (thromboxane A2, PGE2) remains to be defined (Jeremy et al., 1984a) . One possible function, however, is that PGI2 acts as a local cytoprotective agent in a manner similar to that shown in the human stomach (Konturek et al., 1981a,b; Yik et al., 1982) . It follows, therefore, that inhibition of local PGI2 synthesis in the urinary bladder may compromise this organ's local defences against infection or carcinogenesis. Certainly it would appear that exogenous administration of prostanoids exerts beneficial healing effects in bladder pathology (El-Gendi et al., 1982; Mohiuddin et al., 1984) . It is, perhaps, more than coincidence that both schistosomal bladder ulcers and cyclophosphamideinduced haemorrhagic cystitis, which were successfully treated by exogenous prostanoids (El-Gendi et al., 1982; Mohiuddin et al., 1984) , are risk factors in the pathogenesis of bladder cancer (Elem & Burohit, 1983; Fuchs et al., 1981) . It is also of interest that aspirin, which inhibits cyclooxygenase activity (and therefore prostacyclin synthesis), can act as a co-carcinogen in certain animal models (Hasagawa et al., 1984; Chang et al., 1983) . The known association between smoking and an increased risk of bladder carcinoma (Morrison et al., 1984) prompted us to investigate whether cigarette smoke extracts can inhibit PGI2 synthesis by the bladder. Our findings indicate that cigarette smoke extracts and condensates are indeed inhibitors of in vitro PGI2 synthesis by rat bladder tissue. Since both spontaneous PGI2 release and the conversion of AA to PGI2 were inhibited by smoke extracts, it is likely that the action of these compounds is, at least in part, exerted on the enzyme steps (cyclo-oxygenase; PGI2 synthetase) which are beyond phospholipase A2, the enzyme which releases AA from membrane phospholipids to make it available for PGI2 synthesis. This inhibitory action is not likely to be mediated by nicotine alone, since high concentrations of this substance did not inhibit PGI2 synthesis. Cotinine, the main urinary metabolite of nicotine (Matsukura et al., 1984) , also does not appear to exert any significant effect on in vitro PGI2 synthesis in our model. The other components of cigarette smoke evaluated also did not seem to exert any significant inhibitory action, except for 2-naphthylamine, a known carcinogen (Schmeltz & Hoffman, 1977; Purchase et al., 1981) which is present in cigarette smoke (Schmeltz & Hoffman, 1977) . The positive findings with 2-naphthylamine are also of interest, since this compound is a recognised initiator of bladder carcinomas in man and experimental animal models (Schmeltz & Hoffman, 1977; Purchase et al., 1981) . In addition, 2-naphthylamine and related compounds are found in the rubber industry (Checkoway et al., 1981) . It is therefore of interest that in increased incidence of bladder cancer is associated with those working in this industry (Checkoway et al., 1981) .
The fact that the present study was conducted using rat bladders rather than human tissues presents a disadvantage. However, it should be noted that human tissue obtained from pathological bladders or at necropsy may not be appropriate models. Substantial full thickness tissue samples obtained from healthy volunteers raises obvious ethical questions. Measurement of urinary 6-oxoPGF1o (the spontaneous, stable metabolite of PGI2) concentrations as in indirect index of PGI2 production by the bladder is also unsatisfactory, since PGI2 in the urine may also originate from systemic and renal/ureteric sources (Jeremy et al., 1984; Nadler et al., 1983; . Furthermore, the stability and the rate of production of PGI2 in organs other than the bladder may influenced by experimental conditions, such as smoking (Nadler et al., 1983; . Urine contamination from urethral, seminal or uterine tissue may also cause problems. Finally, it is clearly unethical to expose humans to known carcinogens, even in small doses. It would therefore appear that future work evaluating the role played by bladder prostanoids will be largely limited to experimental models, and perhaps to therapeutic intervention trials in humans. The concept that prostaglandins act as cytoprotective barriers which offer some degree of protection from local carcinogenesis/infection clearly deserves further exploration.
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